{"hq_id":"hq-p-bdy-000133","name":"CBD Wellness Products (THC Contamination, Mislabeling, Drug Interactions)","category":{"primary":"personal_care","secondary":"wellness","tags":["CBD","cannabidiol","THC","wellness","FDA","mislabeling","drug interaction","supplement"]},"product_tier":"BDY","overall_risk_level":"moderate","description":"Consumer CBD products (oils, gummies, topicals, beverages) marketed for anxiety, pain, sleep, and 'wellness.' FDA has NOT approved CBD for any consumer wellness use (only Epidiolex for seizures is FDA-approved). Studies show widespread mislabeling: 26% of tested products contained less CBD than labeled, 43% contained more, and 21% contained detectable THC. CBD inhibits cytochrome P450 enzymes — interacting with blood thinners, statins, and anti-seizure medications. CBD is NOT 'natural and safe' by default.","synthesis":{"derived_risk_level":"moderate","synthesis_confidence":0.82,"synthesis_method":"compound_composition","context_used":"human_adult","context_source":"product_users","exposure_modifier":1.026,"vulnerability_escalated":false,"escalation_reason":null,"compounds_resolved":1,"compounds_total":1,"synthesis_date":"2026-03-27","synthesis_version":"1.0.0"},"hazard_summary":{"sensitive_populations":"individuals on prescription medications, drug-tested workers","overall_risk":"moderate","primary_concerns":["Widespread mislabeling: 26% under, 43% over, 21% contain THC (JAMA 2017)","FDA NOT approved for any consumer wellness use","Drug interactions via CYP450 inhibition (blood thinners, statins, seizure meds)","THC contamination causing failed drug tests"],"exposure_routes":"Oral (primary); dermal (topicals — lower systemic absorption)"},"exposure":{"routes":["oral","dermal"],"contact_types":["oral_direct","skin_prolonged"],"users":["adult"],"duration":"minutes","frequency":"daily","scenarios":["Daily CBD oil/gummy consumption for anxiety or sleep","THC contamination causing positive drug test or psychoactive effects","Drug interactions with blood thinners, statins, anti-seizure medications","26% of products contain less CBD than labeled (ineffective)"],"notes":"JAMA 2017: tested 84 CBD products — 26% contained less CBD than labeled, 43% more, 21% had THC. FDA has sent 100+ warning letters to CBD companies for health claims. Only FDA-approved CBD product: Epidiolex (prescription, for Dravet and Lennox-Gastaut seizures). Drug interactions: CBD inhibits CYP3A4 and CYP2C19 — affects metabolism of ~60% of pharmaceutical drugs. Always disclose CBD use to physician/pharmacist."},"consumer_guidance":{"usage_warning":"Disclose CBD use to ALL physicians and pharmacists (drug interactions). Choose products with batch-specific Certificate of Analysis (COA) from ISO-accredited lab. Verify THC content is below detection limit if drug-tested. FDA has NOT approved CBD for anxiety, pain, or sleep — only for seizures (Epidiolex).","safer_alternatives":["Evidence-based treatments for anxiety (therapy, FDA-approved medications)","Evidence-based sleep hygiene (behavioral interventions)","Physician-prescribed Epidiolex for seizure conditions","Melatonin or CBT-I for insomnia (stronger evidence than CBD)"],"red_flags":[{"indicator":"Health claims without FDA approval or clinical evidence","meaning":"Product efficacy unverified.","action":"Consult physician. Check FDA and clinical trial evidence."}],"green_flags":[{"indicator":"FDA-approved, USP-verified, or physician-recommended","meaning":"Verified safety and/or efficacy through established evaluation.","verification":"Check FDA approval status, USP mark, or published clinical evidence."}],"what_to_ask":[{"question":"Is there FDA-approved or peer-reviewed clinical evidence for this product?","why_it_matters":"Health products without evidence may be ineffective or harmful.","good_answer":"FDA-approved or supported by published RCTs.","bad_answer":"Testimonials only or DSHEA-exempt supplement with no clinical evidence."}],"alternatives":[{"name":"Evidence-based treatments for anxiety","notes":"therapy, FDA-approved medications"},{"name":"Evidence-based sleep hygiene","notes":"behavioral interventions"},{"name":"Physician-prescribed Epidiolex for seizure conditions","notes":"Alternative"}]},"regulatory":{"applicable_regulations":[{"jurisdiction":"USA","regulation":"FDA position on CBD (2023)","citation":"FDA Consumer Update","requirements":"FDA has NOT approved CBD as dietary supplement or food additive. CBD products making health claims are unapproved new drugs. 100+ warning letters issued. Only Epidiolex (prescription) is FDA-approved.","compliance_status":null,"effective_date":null,"enforcing_agency":"FDA","penalties":null,"source_ref":null}],"certifications":[],"labeling":{"required_disclosures":[],"prop65_warning":{"required":null,"chemicals":[],"endpoint":null,"notes":null},"ghs_labeling":{"required":null,"signal_word":null,"pictograms":[],"hazard_statements":[],"notes":null},"hidden_ingredients":{"trade_secret_protected":null,"categories_hidden":[],"estimated_count":null,"known_concerns":null,"notes":null},"notes":null},"recalls":[],"regulatory_gap":null,"notes":null},"lifecycle":{"recyclable":true,"disposal_guidance":"Regular waste. Store away from children.","hazardous_waste":false,"expected_lifespan":"1-2_years"},"formulation":{"form":"varies","key_ingredients":[{"hq_id":"hq-c-org-002063","name":"Cannabidiol (CBD)","role":"active_ingredient","concentration_pct":"varies wildly from label"}],"certifications":[]},"materials":{"common":[],"concerning":[],"preferred":[]},"compound_composition":[{"hq_id":"hq-c-org-002063","compound_name":null,"role":"active_ingredient","typical_concentration":"varies wildly from label"}],"identifiers":{"common_names":["cbd wellness products (thc contamination, mislabeling, drug interactions)"],"aliases":[],"manufacturer":null,"brands":[]},"brand_examples":[{"brand":"Johnson & Johnson","manufacturer":"J&J","market_position":"mass_market","notable":"Broad personal care portfolio"},{"brand":"Unilever","manufacturer":"Unilever","market_position":"mass_market","notable":"Global personal care conglomerate"},{"brand":"Procter & Gamble","manufacturer":"P&G","market_position":"mass_market","notable":"Personal care market leader"}],"sources":[{"type":"expert_curation","name":"ALETHEIA Safety Database","date":"2026-03-25"},{"type":"regulation","title":"FDA position on CBD (2023) (FDA Consumer Update)","jurisdiction":"USA","citation":"FDA Consumer Update","id":"src_dfacc588"},{"type":"regulatory","title":"US Food and Drug Administration (FDA)","jurisdiction":"USA","id":"src_82d1cfcd","extraction":"description_reference"}],"meta":{"schema_version":"4.0.0","last_updated":"2026-03-25","timestamp":"2026-05-02T18:16:46.460Z"}}